–
Teva says it will be able to launch generic Viagra in the US in 2017.
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
–
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into an agreement with Pfizer Inc. to settle patent litigation related to Teva’s generic version of Pfizer’s Viagra (sildenafil citrate) tablets.
Under the terms of the agreement Teva will be able to launch its Abbreviated New Drug Application (ANDA) products pursuant to a royalty-bearing license on December 11, 2017, or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
The U.S. Food and Drug Administration (FDA) has already granted tentative approval for Teva’s generic version of Pfizer’s Viagra (sildenafil citrate) tablets, 25, 50, and 100 mg.
Viagra had annual sales of approximately $1.2 billion in the United States, based on IMS sales data as of September 2013.
–
